SCHEMBL1328569

SCHEMBL1328569

Nc1ncccc1Sc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.47
KDM4E B2RXH2 5/20 0.43
HPGD P15428 4/20 0.43
ALDH1A1 P00352 4/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
MAPT P10636 3/20 0.42
NOS3 P29474 2/20 0.42
NOS1 P29475 2/20 0.42
NOS2 P35228 2/20 0.42
NAPRT Q6XQN6 1/20 0.41
EGFR P00533 1/20 0.41
TYMS P04818 1/20 0.41
PDGFRB P09619 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.41
LTA4H P09960 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12474037 0.79 DHFR (0.55) DHFRKDM4EHPGDALDH1A1CYP1A2
SCHEMBL17181782 0.78 ALDH1A1 (0.50) KDM4EHPGDALDH1A1MAPTNOS3
SCHEMBL2129184 0.78 HSD17B10 (0.46) KDM4EHPGDALDH1A1CYP1A2CYP3A4
SCHEMBL5522366 0.78 SIRT1 (0.44) DHFRKDM4EHPGDALDH1A1SIRT1
SCHEMBL14471748 0.77 PKM (0.50) DHFRKDM4EHPGDALDH1A1CYP1A2
SCHEMBL3078836 0.76 NOS3 (0.50) KDM4EHPGDALDH1A1CYP1A2CYP3A4
SCHEMBL2085710 0.76 HPGD (0.39) DHFRKDM4EHPGDCYP1A2CYP3A4
SCHEMBL2657914 0.76 ALDH1A1 (0.42) DHFRKDM4EHPGDALDH1A1SIRT1
SCHEMBL10726183 0.76 ALDH1A1 (0.71) KDM4EHPGDALDH1A1CYP1A2CYP3A4
SCHEMBL21312027 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013204-B1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2015-02-18 EP disclosed
EP-2543667-B1 A method of preparing 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC (US) 2015-01-28 EP disclosed
US-8883828-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2014-11-11 US disclosed
EP-2543667-A9 2-aminopyridine analogs as glucokinase activators Array Biopharma, Inc. (US) 2013-08-21 EP disclosed
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2013-03-14 US disclosed
US-8354540-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA INC. (US) 2013-01-15 US disclosed
EP-2543667-A1 2-aminopyridine analogs as glucokinase activators Array Biopharma, Inc. (US) 2013-01-09 EP disclosed
EP-2543667-A1 2-aminopyridine analogs as glucokinase activators Array Biopharma, Inc. (US) 2013-01-09 EP disclosed
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2011-11-17 US disclosed
US-8022223-B2 2-aminopyridine analogs as glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-06-18 US disclosed
EP-2013204-A2 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2009-01-14 EP disclosed
WO-2007117381-A9 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2008-03-27 WO disclosed
WO-2007117381-A2 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-10-18 WO disclosed
WO-2007091140-A1 SUBSTITUTED PHENYLSULFAMOYL COMPOUNDS AS PPAR AGONISTS PFIZER PRODUCTS INC. (US) 2007-08-16 WO disclosed
US-4237300-A CHEMICAL INTERMEDIATES FOR IMIDAZO(1,2-A)PYRIDINE ANTHELMINTIC AGENTS AS WELL AS BEING A FUNGICIDE MERCK & CO., INC. (US) 1980-12-02 US disclosed
US-4177274-A ANTHELMINTICS MERCK & CO., INC. (US) 1979-12-04 US disclosed
US-4096264-A ANTHELMINTICS MERCK & CO., INC. (US) 1978-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156603-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, PRKCSH DHFR 2326/4885KDM4E 1622/4885HPGD 742/4885
US-20130065901-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 DHFR 1500/4885KDM4E 2172/4885HPGD 704/4885
US-20110281874-A1 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 DHFR 1500/4885KDM4E 2172/4885HPGD 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.